(0)
Follow-on investment, led by Epidarex Capital, closes at £4.24m, following initial £3.2m Seed round in 2020; Caribou Property joins as new investor
Management appointments expand leadership team: Dr Steve Myatt, ex Azeria Therapeutics, to Chief Executive Officer; Dr Carola Ries, ex Roche, to Chief Scientific Officer; Co-founder Dr Luca Cassetta to move from his academic role at Edinburgh University to join as full-time VP Immunology
Funds will accelerate macrophage-based therapeutics R&D portfolio and target discovery capability; expansion of facilities in Edinburgh and Cambridge
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has closed a follow-on financing of £4.24 million from its 2020 Seed round, bringing the total amount raised to £7.44m.
Endocrine system 4: adrenal glands
nursingtimes.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nursingtimes.net Daily Mail and Mail on Sunday newspapers.
Muchomůrka zleená: V IKEMu už léčili první letošní otravu
blesk.cz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from blesk.cz Daily Mail and Mail on Sunday newspapers.
Potential New Treatment against Melanoma
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Updated Jul 25, 2021 | 12:30 IST
A recent study provided insights into fighting tuberculosis and other infectious diseases around the world by analyzing how individual immune cells react to the bacterium that causes the deadly disease. New cell-analysis technique to fight tuberculosis developed: Study | Photo Credit: Representative Image
New York: During a new study, researchers paved the way for new vaccine strategies against tuberculosis, and provided insights into fighting other infectious diseases around the world by analyzing how individual immune cells react to the bacterium that causes this deadly disease. The cutting-edge technologies were developed in the lab of Dr David Russell, the William Kaplan Professor of Infection Biology in the Department of Microbiology and Immunology in the College of Veterinary Medicine, and detailed in new research published in the Journal of Experimental Medicine on July 22. For years, Russell s lab has so